02.02.2024 12:44:59 - dpa-AFX: Regeneron Pharmaceuticals Q4 Profit Decreases, but beats estimates

WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced earnings
for fourth quarter that decreased from last year but beat the Street estimates.
The company's bottom line totaled $1.16 billion, or $10.19 per share. This
compares with $1.20 billion, or $10.50 per share, in last year's fourth quarter.

Excluding items, Regeneron Pharmaceuticals reported adjusted earnings of $1.37
billion or $11.86 per share for the period.

Analysts on average had expected the company to earn $10.77 per share, according
to figures compiled by Thomson Reuters. Analysts' estimates typically exclude
special items.

The company's revenue for the quarter rose 0.6% to $3.43 billion from $3.41
billion last year.

Regeneron Pharmaceuticals earnings at a glance (GAAP) :

-Earnings (Q4): $1.16 Bln. vs. $1.20 Bln. last year.
-EPS (Q4): $10.19 vs. $10.50 last year.
-Analyst Estimates: $10.77
-Revenue (Q4): $3.43 Bln vs. $3.41 Bln last year.


Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
Regeneron Pharmaceuticals 881535 NASDAQ 990,500 03.06.24 21:41:05 +10,340 +1,05% 989,950 991,030 980,160 980,160

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH